A day AGI rjs shares Joe’s post on filing of IND. Joe

New Post Public Reply Private Reply Replies (0) Message Board
tc2000chartreader OrlandoJohn #18824
396
A day AGI rjs shares Joe’s post on filing of IND.

Joe comment

In my opinion long term sustained memory like our 10 year breast cancer vaccine data that was just released is the only way, and none of the other pathways like mRNA have that or significant positive with big benefit data, unless I missed it, so, a lotta work ahead!

Digi comment

There is no long term sustained protection from the coronavirus. Crap, make a cold vaccine and maybe we could believe you. Reality is Joe, it can't be done due to the mutations that take place in a short amount of time. You really want liability or did you get Nu Generex into the "Not being able to be prosecuted thing". Reality Joe.

Joe comment

Chuck Merchant that is a ridiculous statement, get facts Chuck, a subunit pathway works with epitopes, epitopes change minutely from one strain to another, example, SARS Corona 2002 is a 80 percent match from SARS to COVID 19 so to enlighten you a vaccine made for SARS with subunit antibody (Humeral) and Cellular cd4 and 8 protection would work fine with protection today, its the ones doing full spike protein that have the problems with your ridiculous uninformed comment. Comments like this are not smart, irresponsible and for sure disgustingly stupid.

Rjs comment

Chuck Merchant hey bud, the long term memory Joe referred to was proven in the Phase II breast cancer vaccine study cs the Phase I prostate vaccine study. That’s remarkable and confirms optimism for the Ii-Key CD 4, CD 8 whole vaccine approach. Such a peptide vaccine can later be specially designed for future mutations. Testing for safety, immunological response and efficacy is key though for the NuGenerex Covid vaccine. Joe can correct any of that if I’m wrong.

Digi comment

Honest question Joe. Would you take the first vaccine that Nu Generex produces?


BTW Joe, you do know that the SARS vaccine that was given to the Chinese folks produced about a 90% fatality rate when this second wave came around. It's fact if you check it. Point is Joe, it seems like there is no vaccine that can be made to protect folks. If I am wrong, then please provide me with FACTS to show that I am wrong. Fair enough?

Joe comment

Chuck Merchant I would never take a rna, dna and especially a mRNA vaccine if it’s anything less then 100 percent which they will not be that I guarantee, and if not 100 percent he’ll no, because the off targets will kill me, and if I get it again with that vaccine the off targets will kill me like cytokine storm and any of the other 20-30 off target auto immune events that could occur, but first and foremost you would have to show me any data that these pathways have any data prior that is significant positive and gives benefit, but there is none because after all the failures they finally figured it out for Covid and that’s just bullshit.


And yes I would take the first vaccine Generex produces because we never had off targets and we are the only one unless I’m wrong and missed something that has significant positive benefit data from something else, again I could be wrong but if I am someone needs to prove it to me.

And to date no ones proved nothing. Period! End of story!

Chuck Merchant have no idea what vaccine or pathway your talking about, I do know your warp speed leader from GSK killed more people then anyone in England on his GSK vaccines and ooops I forgot all those pediatrics. And I’m sure if o viral vector or use of all spike protein, non dehumanized and live virus particles it killed more then you know.

You should really stay away from science Chuck and stick to computers, oops i forgot that great philanthropist Bill Gates who couldn’t solve his viruses in his own product at Microsoft and has made 100 times more then he pretended to give away will solve this problem, hahahahaha!

Digicomment

Covid has a 3-6 month memory in our systems. Already proven. Joe just wants the price to spike. And BTW, mRNA is a disaster. It can change systematic DNA to what the mRNA wants it to do. Do some checking on it RJ.

Joe comment

Chuck Merchant says who show me the data as the fda would say

Chuck Merchant antibodies disappear in 30-60 days after getting over Covid, and no one like Moderna wants to give their full data, and my belief it’s the same otherwise from their phase one the first thing I’d be trumpeting is 30, 60, 90 days still robust antibody with cd4, cd8 long term memory tcell activation, but no one is saying that, and please with Oxford they are notorious exaggerators, it’s a really good business buying or giving someone 2-300 million, spend another 500 million to know what you know already, failure but your big time Lobbiest sin Washington plus your buddies give you a 1.6 billion dollar contract and make even with failure 100’s of millions, now that’s a great business, none of the partnerships would have ever of happened with big pharma if Covid did not take place and all the free cash, and all those great Lobbiest sin Washington that work for big pharma cause they pay millions a quarter, it’s really funny to me all the contracts went to companies with zero product but they got contracts only after they bought someone else’s product, hahaha do your DD.

Chuck Merchant and stop with the ridiculous comments, talk to me when I’m right in 3 mos.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 410

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 319

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 275

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 298

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 180

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 232

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 317

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 407

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 409

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

Waymo and Hyundai Unite for a Revolutionary Ride-Hailing Future

Updated Category News Views 123

Waymo and Hyundai Join Forces for Autonomous Innovations Recently, Hyundai Motor Company and Waymo, a leader under the umbrella of Alphabet Inc., outlined an exciting multi-year partnership aimed at revolutionizing the autonomous taxi scene. Central to this collaboration is the integration of Waymo's advanced sixth-generation autonomous technology, widely recognized as...

Continue Reading
Klépierre Announces Update on Voting Rights and Shares

Updated Category News Views 158

Klépierre Shares and Voting Rights Overview In a significant update regarding the total voting rights and shares, Klépierre, a renowned shopping mall leader in Europe, has disclosed vital information as of April 30, 2025. This information is crucial for current and potential investors as it sheds light on the company’s governance and shareholding structure. Current...

Continue Reading
Exciting New Volleyball Franchise to Debut in Minnesota

Updated Category News Views 253

New Franchise Spotlight: Minnesota Joins Major League Volleyball Major League Volleyball (MLV) is set to enhance its dynamic league with the addition of Minnesota as a franchise market. This exciting development will see Minnesota entering the competition in 2027, bringing the total number of teams in the league to 11. Ownership and Leadership Team The Minnesota franchise...

Continue Reading
Insights on Challenger Energy Group's Strategic Acquisition Plans

Updated Category News Views 161

Latest Developments in the Challenger Energy Acquisition Dear Fellow Shareholders, There’s an exciting journey unfolding for Challenger Energy Group plc as the company is taking significant strides towards a proposed all-share acquisition that holds the promise of redefining our strategic landscape. Just recently, Challenger and Sintana Energy announced the publication...

Continue Reading
Emboa Medical's Innovative Catheter Revolutionizes Stroke Treatment

Updated Category News Views 347

Revolutionizing Stroke Treatment with Innovative Technology Emboa Medical Inc., a pioneering medical device startup, is leading the charge in improving outcomes for stroke patients by developing a revolutionary catheter inspired by nature. The company’s creation, a novel microstructured catheter known as the TRAP (Thrombus Retrieval Aspiration Platform), utilizes...

Continue Reading